{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:18Z","timestamp":1779527358443,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00854-1","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:46:07Z","timestamp":1776091567000},"page":"843-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2201","authenticated-orcid":false,"given":"Boulos","family":"Haraoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Galos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vaillancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Sampalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Khraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003533","volume":"10","author":"N Hassen","year":"2024","unstructured":"Hassen N, Lacaille D, Xu A, et al. National burden of rheumatoid arthritis in Canada, 1990\u20132019: findings from the Global Burden of Disease Study 2019 - a GBD collaborator-led study. RMD Open. 2024;10:e003533.","journal-title":"RMD Open"},{"key":"854_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"854_CR3","unstructured":"Pfizer Canada ULC. Xeljanz (Product Monograph) 2022 [updated 04\/07\/2024]. https:\/\/pdf.hres.ca\/dpd_pm\/00065725.PDF. Accessed 24 July, 2024."},{"key":"854_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/acr.24966","volume":"75","author":"B Haraoui","year":"2023","unstructured":"Haraoui B, Khraishi M, Choquette D, et al. Effectiveness and safety of tofacitinib in Canadian patients with rheumatoid arthritis: primary results from a prospective observational study. Arthritis Care Res (Hoboken). 2023;75:240\u201351.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"854_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s40744-024-00719-5","volume":"11","author":"B Haraoui","year":"2024","unstructured":"Haraoui B, Khraishi M, Choquette D, et al. Tofacitinib safety and effectiveness in Canadian patients with rheumatoid arthritis by cardiovascular risk enrichment: subanalysis of the CANTORAL Study. Rheumatol Ther. 2024;11:1629\u201348.","journal-title":"Rheumatol Ther"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/mr\/road063","volume":"34","author":"M Kuwana","year":"2024","unstructured":"Kuwana M, Sugiyama N, Momohara S, et al. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: interim analysis of post-marketing surveillance. Mod Rheumatol. 2024;34:272\u201386.","journal-title":"Mod Rheumatol"},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3899\/jrheum.211066","volume":"49","author":"M Movahedi","year":"2022","unstructured":"Movahedi M, Cesta A, Li X, Keystone EC, Bombardier C. Physician- and patient-reported effectiveness are similar for tofacitinib and TNFi in rheumatoid arthritis: data from a rheumatoid arthritis registry. J Rheumatol. 2022;49:447\u201353.","journal-title":"J Rheumatol"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3899\/jrheum.2023-0752","volume":"51","author":"DA Pappas","year":"2024","unstructured":"Pappas DA, O\u2019Brien J, Moore PC, et al. Treatment patterns and effectiveness of tofacitinib in patients initiating therapy for rheumatoid arthritis: results from the CorEvitas Rheumatoid Arthritis Registry. J Rheumatol. 2024;51:452\u201361.","journal-title":"J Rheumatol"},{"key":"854_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001174","volume":"6","author":"A Finckh","year":"2020","unstructured":"Finckh A, Tellenbach C, Herzog L, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020;6:e001174.","journal-title":"RMD Open"},{"key":"854_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.","journal-title":"Arthritis Res Ther"},{"key":"854_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.","journal-title":"Arthritis Res Ther"},{"key":"854_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595","volume":"7","author":"GR Burmester","year":"2021","unstructured":"Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37,066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595.","journal-title":"RMD Open"},{"key":"854_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open-label, randomised controlled study ORAL surveillance. Ann Rheum Dis. 2023;82:901\u201310.","journal-title":"Ann Rheum Dis"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u201329.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00854-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:44Z","timestamp":1779526004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00854-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00854-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Boulos Haraoui has received grants and honoraria from AbbVie, Amgen, Eli Lilly, Gilead Sciences, Janssen, Pfizer Inc, and UCB. Denis\u00a0Choquette has received grants and honoraria from AbbVie, Amgen, CIHR, Eli Lilly, Fresenius Kabi, Novartis, Pfizer\u00a0Inc, Sandoz, Teva Pharmaceuticals, and Viatris. Cristina Sciortino is an employee and shareholder of Pfizer Inc. Corina Galos and Patrice Roy were employees and shareholders of Pfizer Inc at the time of the analysis. David\u00a0Gruben is an employee and shareholder of Pfizer Inc. Julie\u00a0Vaillancourt and John S. Sampalis are employees of JSS Medical Research Inc., which was a paid consultant to Pfizer in connection with the study development, management, conduct, data collection, and data analysis. Majed Khraishi has received honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer\u00a0Inc, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"CANTORAL was conducted in compliance with the Declaration of Helsinki, International Council for Harmonisation Guidelines for Good Clinical Practice, and local country regulations. The study protocol was approved by Advarra (MOD00903929) and the Institutional Review Board or Independent Ethics Committee at each center, per institutional or clinical requirements. Patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}